Health Condition 1: - Health Condition 2: - Health Condition 3: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: .1 Patients of either sex with age between 18 and 60 years 2 Patients with Superficial externalwounds requiring dressing 3. Solitary wound not less than 1 inches (2.5 cm) in diameter 4 Patienwilling to participate in the study for 1 month
Exclusion criteria
Exclusion criteria: 1Known allergy/hypersensitivity to any of the components of the dressing 2.Wound associated with fracture 3.Wound associated with skin disorder that is chronic or currently active like psoriasis, eczema 4.Neurological deficit at wound site 5.Hemoglobin level 6.Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction (defined as S.Creatinine > 1.2 mg/dl) 7.Known cases of Diabetes Mellitus, AIDS & other sexually transmitted diseases, Malignancy or known history of coagulopathy 8.Patients receiving immune-suppressive medication 9. Pregnancy or lactation 10.Varicose veins/Deep Vein Thrombosis 11.Wounds requiring full thickness graft 12.Patients where a reference wound cannot be treated in isolation fromother wounds. 13.H/o hypersensitivity to any of thetrial drugs or their ingredients. 14.Patient taking participationin any other clinical trial 15.Any other condition which the Investigatorthinksmay jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures Time to complete re-epithelialization (Time Frame: 4 weeks.)Timepoint: Primary Outcome Measures Time to complete re-epithelialization (Time Frame: 4 weeks.) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Incidence of wound infection (Time Frame: 4 weeks 2.Pain during dressing changes (score) [Time Frame: 2 weeks] 3.Any systemic effect after treatment CBC, blood glucose, electrolyte, hepatic and renal functions will be analyzed to find any changes. 4.Incidence of Blistering [Time Frame: 0-6 days] 5.Incidence of adverse reactionsTimepoint: 7th, 14th, 21 stand 28th days | — |
Countries
India
Contacts
Central council for Research in Ayurvedic sciences,